{"schema_version":"secwatch.filing_event.v1","accession":"0001708599-26-000018","form_type":"8-K","ticker":"SER","cik":"0001708599","company_name":"Serina Therapeutics, Inc.","filed_at":"2026-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.961993+00:00","generated_at":"2026-05-15T09:02:10.197515+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Serina Therapeutics reports FY2025 net loss of $19.4M; SER-252 Phase 1b initiated; up to $30M financing closed","bullets":["Net loss $19.4M ($1.91/share) vs $11.1M ($1.51/share) in FY2024; operating expenses rose to $24.2M from $17.1M.","FDA IND cleared for SER-252 (advanced Parkinson's); first patient dosed in Phase 1b trial in February 2026.","Private placement of up to $30M closed; $16M received as of March 23, 2026; Greg Bailey appointed Co-Chairman.","ATM program raised $12.9M from 3.5M shares at avg $3.72; additional $10M raised in 2026.","Cash and cash equivalents $3.1M as of December 31, 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001708599-26-000018","json":"https://secwatch.observer/filing/0001708599-26-000018.json","markdown":"https://secwatch.observer/filing/0001708599-26-000018.md","text":"https://secwatch.observer/filing/0001708599-26-000018.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/0001708599-26-000018-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/ser-20260325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:02:10.197515+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2665892a185b5f7dbbec37ca6b35d667c2fb4ca3","claim":"Serina Therapeutics, Inc. reported the year ended December 31, 2025 results: net income $19.4 million, EPS $(1.91) per basic and diluted share.","evidence_excerpt":"The net loss attributable to Serina common stockholders for the year ended December 31, 2025 was $19.4 million, or $(1.91) per basic and diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1708599/000170859926000018/0001708599-26-000018-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the year ended December 31, 2025"},{"label":"Net income","value":"$19.4 million"},{"label":"EPS","value":"$(1.91) per basic and diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}